Core Insights - The article discusses the advancements in cancer treatment and detection technologies, highlighting the significant progress made by Oncolytics Biotech Inc. and other biotech companies in 2025 amid rising global cancer rates [1][2][3] Company Developments - Oncolytics Biotech Inc. has made key regulatory and clinical advancements in 2025, particularly with its immunotherapy drug pelareorep, which has received safety and regulatory clearance to advance enrollment in its pancreatic cancer study [3][4] - The company presented new efficacy and safety data for pelareorep at the 2025 ASCO Gastrointestinal Cancers Symposium, showing strong responses in anal cancer and confirming a favorable safety profile in pancreatic cancer [5][6] - Oncolytics is set to advance its pancreatic cancer trial (GOBLET Cohort 5) with 30 patients participating, evaluating pelareorep in combination with modified FOLFIRINOX, with or without atezolizumab [4][5] Industry Trends - The global cancer therapy market is projected to reach approximately $285.96 billion by 2030, with a compound annual growth rate (CAGR) of 9.12%, indicating significant market expansion for advanced oncology solutions [2] - The collaboration between GRAIL, Inc. and Quest Diagnostics aims to improve access to early cancer detection through GRAIL's Galleri test, enhancing provider access via Quest's connectivity system [10][11] - Renovaro Inc. has entered into a binding LOI to acquire Predictive Oncology Inc., which will enhance its capabilities in cancer diagnostics and therapeutics, leveraging Predictive's extensive biobank and AI-driven drug discovery platform [12][13][14]

Core Insights - Oncolytics Biotech Inc. is making significant progress in 2025 with its immunotherapy pelareorep, particularly in pancreatic cancer and other hard-to-treat cancers [1][2][4] - The company has received regulatory clearance to advance its pancreatic cancer study and presented new efficacy and safety data at the 2025 ASCO Gastrointestinal Cancers Symposium [1][2][4] Regulatory Developments - The German Regulatory Agency has approved the continuation of the pancreatic cancer study, allowing full enrollment after a positive safety review [3][6] - The study involves 30 patients in Stage 1, evaluating pelareorep in combination with modified FOLFIRINOX and atezolizumab [6][9] Clinical Data and Efficacy - New clinical results presented at ASCO GI 2025 demonstrate pelareorep's potential in pancreatic and anal cancers, indicating strong safety and efficacy signals [4][6] - Patients receiving pelareorep with atezolizumab show stronger responses than expected based on previous studies with checkpoint inhibitors alone [6] Future Milestones - Oncolytics is entering a pivotal year with multiple upcoming milestones, including additional data readouts and interactions with regulatory agencies [5][7] - The company is preparing for registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [12]

Core Insights - Oncolytics Biotech Inc. is making significant progress in 2025 with advancements in regulatory and clinical areas, particularly for its immunotherapy pelareorep in hard-to-treat cancers [1][2][4] - Recent clinical data presentations at the ASCO Gastrointestinal Cancers Symposium have highlighted pelareorep's strong safety and efficacy signals in pancreatic and anal cancers [1][4][5] Regulatory Developments - The German Regulatory Agency has approved the continuation of the pancreatic cancer study, allowing full enrollment after a positive safety review [3][5] - Oncolytics has received positive feedback from regulators, facilitating the advancement of its pancreatic cancer study toward full enrollment [2][5] Clinical Data and Efficacy - At ASCO GI 2025, new clinical results were presented, confirming pelareorep's potential in pancreatic and anal cancers, which may lead to larger registration-enabling clinical trials [4][5] - Pelareorep has shown a favorable safety profile and strong efficacy signals when combined with modified FOLFIRINOX and atezolizumab in pancreatic cancer [5][8] Future Outlook - Oncolytics is entering a pivotal year with multiple upcoming milestones, including additional data readouts and interactions with regulatory agencies that could accelerate future trials [5][6] - The company is focused on advancing its clinical program in gastrointestinal cancers and moving toward registration-enabling studies in breast cancer [7][10]

Core Points - Oncolytics Biotech Inc. received a delinquency notification from Nasdaq due to its ordinary shares closing below $1.00 for 30 consecutive business days [1][2] - The company has until August 12, 2025, to regain compliance with the minimum bid price requirement [1][2] - If the bid price reaches or exceeds $1.00 for at least 10 consecutive business days before the deadline, Nasdaq will confirm compliance [2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent delivered intravenously [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses [4][5] - The company is conducting combination clinical trials with pelareorep and has received Fast Track designation from the FDA for its studies in metastatic breast cancer and pancreatic cancer [5]

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in treating metastatic breast cancer and pancreatic cancer [3][4] - Pelareorep works by inducing anti-cancer immune responses and transforming "cold" tumors into "hot" tumors, enhancing the effectiveness of cancer treatments [3] Leadership Change - Matt Coffey, Ph.D., the President and CEO, will not return after a medical leave of absence and has officially stepped down due to ongoing health concerns [1][2] - Wayne Pisano, Chair of the Board of Directors, will serve as Interim CEO while the company initiates a search for a new CEO [2] Clinical Development - Pelareorep has demonstrated synergies with multiple approved oncology treatments and is currently involved in combination clinical trials for solid malignancies [4] - The company is advancing towards registrational studies for pelareorep in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]

Oncolytics Biotech Inc. (ONCY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individu ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 22, 2025 /PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25 in San Francisco. This year's event is particularly critical as researchers highlight the alarming rise in cancer rates among people under 50, with gastrointestinal cancers leading the increase. Colorectal and pancreatic cancers, two of the top t ...

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients SAN DIEGO and CALGARY, AB, Jan. 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today provided details from the abstracts featuring pelareorep that are being p ...

Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds gre ...

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB, Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with mo ...